Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Roche has taken its next big step into the allogeneic CAR-T field, this time tying up alongside Poseida Therapeutics $PSTX with $220 million in upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

John Carroll

Editor & Founder

Aayushi Pratap

News Reporter

Sign up to read this article for free.

Danish biotech Gubra touts early weight loss data in hot amylin field

After stock slides, Amgen addresses bone density talk on obesity drug

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

Editor & Founder

News Reporter

Sign up to read this article for free.

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner